NASDAQ
04.09.25 | 21:59
1,510 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.08. | Shattuck Labs closes $103 million private placement led by OrbiMed | 1 | Investing.com | ||
| 26.08. | Shattuck Labs, Inc.: Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 26.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | H.C. Wainwright maintains Neutral rating on Shattuck Labs stock as FDA clears IND | 1 | Investing.com | ||
| 21.08. | Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease | 265 | GlobeNewswire (Europe) | - SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases - - The Company... ► Artikel lesen | |
| 14.08. | Leerink Partners senkt Kursziel für Shattuck Labs auf 2 $ | 1 | Investing.com Deutsch | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 14.08. | Shattuck Labs stock price target lowered to $2 by Leerink Partners | 1 | Investing.com | ||
| 14.08. | Shattuck Labs GAAP EPS of -$0.24 in-line | 2 | Seeking Alpha | ||
| 14.08. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights | 87 | GlobeNewswire (Europe) | - Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 - - On track to dose first participant in... ► Artikel lesen | |
| 05.08. | Shattuck Labs stock soars after $103 million private placement | 4 | Investing.com | ||
| 05.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08. | Shattuck Labs, Inc.: Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million | 5 | GlobeNewswire (USA) | ||
| 15.07. | Shattuck Labs: Aktionäre wählen Direktoren und bestätigen Wirtschaftsprüfer auf jährlicher Hauptversammlung | 1 | Investing.com Deutsch | ||
| 15.07. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.05. | Shattuck Labs GAAP EPS of -$0.27 beats by $0.01 | 1 | Seeking Alpha | ||
| 01.05. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.05. | Shattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights | 147 | GlobeNewswire (Europe) | - Company advances SL-325 program with an IND filing expected in the third quarter of 2025 - - Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027... ► Artikel lesen | |
| 01.05. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,215 | +0,11 % | dpa-AFX-Überblick: UNTERNEHMEN vom 29.08.2025 - 15.15 Uhr | ROUNDUP: Gerresheimer bekommt überraschend neuen Finanzchef - Aktie erholt DÜSSELDORF - Der zuletzt schwächelnde Pharmaverpackungshersteller Gerresheimer bekommt überraschend einen neuen Finanzchef.... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,905 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| EVOTEC | 5,702 | -2,70 % | Insiderkäufe und Datenpanne - Evotec, naoo AG, PayPal | In der deutschen Wirtschaft herrscht zunehmend Unruhe und nicht jeder Vorstand sitzt mehr sicher im Sattel. Der Volkswagen Konzern ist ins Straucheln geraten und die Frage, ob der Vorstandschef Oliver... ► Artikel lesen | |
| VERA THERAPEUTICS | 21,900 | -4,62 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 35,510 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 19,760 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 33,175 | 0,00 % | Mineralys Therapeutics closes $287.5 million public offering | ||
| TAYSHA GENE THERAPIES | 3,260 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 37,130 | -2,75 % | Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum | ||
| PRAXIS PRECISION MEDICINES | 46,090 | -1,01 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| IMMUNOME | 9,800 | -4,39 % | Immunome Inc. - 10-Q, Quarterly Report | ||
| PHATHOM PHARMACEUTICALS | 12,000 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| BIONTECH | 89,10 | +3,42 % | BioNtech Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| EDGEWISE THERAPEUTICS | 14,620 | -0,10 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Sept. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,805 | 0,00 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress |
Das Unternehmen SHATTUCK LABS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,510 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.